Virbac SA
PAR:VIRP

Watchlist Manager
Virbac SA Logo
Virbac SA
PAR:VIRP
Watchlist
Price: 334.5 EUR -0.74% Market Closed
Market Cap: 2.8B EUR
Have any thoughts about
Virbac SA?
Write Note

Relative Value

The Relative Value of one VIRP stock under the Base Case scenario is 455.26 EUR. Compared to the current market price of 334.5 EUR, Virbac SA is Undervalued by 27%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VIRP Relative Value
Base Case
455.26 EUR
Undervaluation 27%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
39
vs Industry
47
Median 3Y
2.2
Median 5Y
2.1
Industry
2.6
Forward
2
vs History
55
vs Industry
20
Median 3Y
20.8
Median 5Y
21.6
Industry
23
Forward
18.3
vs History
74
vs Industry
19
Median 3Y
23.7
Median 5Y
18.8
Industry
17.8
vs History
74
vs Industry
16
Median 3Y
31.7
Median 5Y
30.7
Industry
25.4
vs History
65
vs Industry
24
Median 3Y
3.1
Median 5Y
3.2
Industry
2.2
vs History
44
vs Industry
46
Median 3Y
2.2
Median 5Y
2.2
Industry
2.8
Forward
2
vs History
90
vs Industry
54
Median 3Y
3.9
Median 5Y
4.1
Industry
5.4
vs History
52
vs Industry
30
Median 3Y
10.9
Median 5Y
11.1
Industry
13.7
Forward
10.1
vs History
71
vs Industry
28
Median 3Y
13.5
Median 5Y
15.1
Industry
17.2
Forward
12.8
vs History
74
vs Industry
21
Median 3Y
22.6
Median 5Y
19.8
Industry
16.5
vs History
68
vs Industry
11
Median 3Y
39.9
Median 5Y
28.8
Industry
19.3
vs History
65
vs Industry
32
Median 3Y
2.4
Median 5Y
2.2
Industry
2

Multiples Across Competitors

VIRP Competitors Multiples
Virbac SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Virbac SA
PAR:VIRP
2.8B EUR 2.1 19.9 10.5 12.8
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
746.8B USD 18.3 89.2 48 53.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.4 27.8
US
Johnson & Johnson
NYSE:JNJ
365.6B USD 4.2 24.9 12 15.7
US
Merck & Co Inc
NYSE:MRK
249.1B USD 3.9 20.5 10.4 12.4
CH
Roche Holding AG
SIX:ROG
208.6B CHF 3.6 18.1 10.2 12.1
CH
Novartis AG
SIX:NOVN
181.4B CHF 4.2 12.6 10 14.8
UK
AstraZeneca PLC
LSE:AZN
159.6B GBP 4.1 31.4 169.3 253.8
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
FR
Virbac SA
PAR:VIRP
Average P/E: 31.5
19.9
54%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
89.2
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
24.9
-22%
US
Merck & Co Inc
NYSE:MRK
20.5
7 336%
CH
Roche Holding AG
SIX:ROG
18.1
32%
CH
Novartis AG
SIX:NOVN
12.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.4
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Discover More
Back to Top